Hims & Hers Health (HIMS) Projected to Post Earnings on Monday

Hims & Hers Health (NYSE:HIMS - Get Free Report) is projected to issue its Q4 2024 quarterly earnings data after the market closes on Monday, February 24th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $494.56 million for the quarter. Hims & Hers Health has set its Q1 2025 guidance at EPS and its FY 2025 guidance at EPS.Parties that wish to register for the company's conference call can do so using this link.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded down $11.37 on Tuesday, reaching $39.95. The stock had a trading volume of 82,558,275 shares, compared to its average volume of 21,022,680. Hims & Hers Health has a fifty-two week low of $9.67 and a fifty-two week high of $72.98. The business's 50-day moving average price is $35.62 and its two-hundred day moving average price is $26.25. The stock has a market cap of $8.73 billion, a P/E ratio of 90.79 and a beta of 1.35.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 268,932 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the sale, the insider now directly owns 169,803 shares of the company's stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the transaction, the insider now owns 184,947 shares of the company's stock, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,097,578 shares of company stock valued at $38,080,320. Corporate insiders own 17.71% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Leerink Partners boosted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday. TD Cowen restated a "buy" rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Finally, Citigroup increased their price objective on shares of Hims & Hers Health from $25.00 to $27.00 and gave the company a "sell" rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of "Hold" and an average target price of $33.40.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.